CY1121230T1 - Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου - Google Patents
Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρουInfo
- Publication number
- CY1121230T1 CY1121230T1 CY20181101376T CY181101376T CY1121230T1 CY 1121230 T1 CY1121230 T1 CY 1121230T1 CY 20181101376 T CY20181101376 T CY 20181101376T CY 181101376 T CY181101376 T CY 181101376T CY 1121230 T1 CY1121230 T1 CY 1121230T1
- Authority
- CY
- Cyprus
- Prior art keywords
- hydroxide
- pharmaceutical compositions
- iron oxide
- compositions containing
- containing iron
- Prior art date
Links
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000037406 food intake Effects 0.000 abstract 1
- 210000000214 mouth Anatomy 0.000 abstract 1
- 230000007928 solubilization Effects 0.000 abstract 1
- 238000005063 solubilization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/009—Sachets, pouches characterised by the material or function of the envelope
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Φαρμακευτικές συνθέσεις για χορήγηση από το στόμα, και ιδιαίτερα για χορήγηση ως σύστημα μεταφοράς από το στόμα που προορίζεται για κατάποση άμεσα ή είναι ικανό για διαλυτοποίηση στη στοματική κοιλότητα, που περιέχει οξείδιο-υδροξείδιο του σιδήρου σε υψηλή φόρτωση.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07120837 | 2007-11-16 | ||
EP08848615.4A EP2222285B1 (en) | 2007-11-16 | 2008-11-13 | Pharmaceutical compositions |
PCT/EP2008/065444 WO2009062993A1 (en) | 2007-11-16 | 2008-11-13 | Pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121230T1 true CY1121230T1 (el) | 2020-05-29 |
Family
ID=39535152
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100099T CY1118496T1 (el) | 2007-11-16 | 2017-01-24 | Φαρμακεyτικες συνθεσεις |
CY20181101376T CY1121230T1 (el) | 2007-11-16 | 2018-12-19 | Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου |
CY20221100224T CY1125300T1 (el) | 2007-11-16 | 2022-03-21 | Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100099T CY1118496T1 (el) | 2007-11-16 | 2017-01-24 | Φαρμακεyτικες συνθεσεις |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20221100224T CY1125300T1 (el) | 2007-11-16 | 2022-03-21 | Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου |
Country Status (35)
Country | Link |
---|---|
US (13) | US9561251B2 (el) |
EP (6) | EP3143992B1 (el) |
JP (7) | JP5466164B2 (el) |
KR (2) | KR101590115B1 (el) |
CN (7) | CN104688702A (el) |
AR (1) | AR069312A1 (el) |
AU (1) | AU2008322963B2 (el) |
BR (1) | BRPI0820308B8 (el) |
CA (1) | CA2700444C (el) |
CO (1) | CO6280398A2 (el) |
CY (3) | CY1118496T1 (el) |
DK (4) | DK3492069T3 (el) |
ES (5) | ES2951457T3 (el) |
FI (1) | FI3895699T3 (el) |
GT (1) | GT201000144A (el) |
HK (1) | HK1207298A1 (el) |
HR (4) | HRP20230588T3 (el) |
HU (2) | HUE031293T2 (el) |
IL (2) | IL205726A (el) |
LT (3) | LT3492069T (el) |
MA (1) | MA31898B1 (el) |
MX (1) | MX2010005346A (el) |
MY (2) | MY156383A (el) |
NZ (1) | NZ585435A (el) |
PH (1) | PH12015500727A1 (el) |
PL (4) | PL3895699T3 (el) |
PT (5) | PT2222285T (el) |
RU (2) | RU2493831C3 (el) |
SA (1) | SA112340044B1 (el) |
SG (1) | SG188789A1 (el) |
SI (4) | SI3895699T1 (el) |
TN (1) | TN2010000152A1 (el) |
TW (2) | TWI468167B (el) |
WO (1) | WO2009062993A1 (el) |
ZA (1) | ZA201004256B (el) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
JP5756598B2 (ja) | 2007-02-06 | 2015-07-29 | メディカル リサーチ カウンシル | リガンド修飾ポリオキソヒドロキシ金属イオン物質、それらの使用およびそれらの調製方法 |
TWI468167B (zh) | 2007-11-16 | 2015-01-11 | 威佛(國際)股份有限公司 | 藥學組成物 |
GB0814326D0 (en) * | 2008-08-05 | 2008-09-10 | Medical Res Council | Phosphate binding materials and their uses |
US20110097401A1 (en) | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
CN102573807A (zh) * | 2009-07-21 | 2012-07-11 | 凯克斯生物制药公司 | 柠檬酸铁剂型 |
AU2014218455B2 (en) * | 2009-07-21 | 2016-11-24 | Keryx Biopharmaceuticals, Inc. | Ferric Citrate Dosage Forms |
DK3735962T3 (da) * | 2013-11-27 | 2024-06-24 | Vifor Fresenius Medical Care Renal Pharma Ltd | Farmaceutisk sammensætning, omfattende fosfatbindemiddelspartikler |
EP3157516A4 (en) | 2014-06-22 | 2017-12-13 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
US20170259241A1 (en) * | 2014-09-10 | 2017-09-14 | Lupin Limited | A manufacturing process for an iron containing adsorbent |
JP5757493B1 (ja) * | 2014-09-24 | 2015-07-29 | 富田製薬株式会社 | 経口型鉄分補給用固形組成物及びその製造方法 |
CN104688706B (zh) * | 2015-04-01 | 2017-07-14 | 成都欣捷高新技术开发有限公司 | 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法 |
US10258647B2 (en) | 2015-09-01 | 2019-04-16 | Particle Dynamics International, Llc | Iron-polysaccharide complexes and methods for the preparation thereof |
CN107397759A (zh) * | 2016-05-19 | 2017-11-28 | 欣凯医药化工中间体(上海)有限公司 | 基于铁的氢氧化物-降解的碳水化合物的磷结合剂、其制备方法及其应用 |
EP3829761A1 (en) | 2018-07-30 | 2021-06-09 | Interquim S.A. | Process for preparing an adsorbent for phosphate in aqueous medium |
US20210308054A1 (en) * | 2018-08-10 | 2021-10-07 | Kissei Pharmaceutical Co., Ltd. | Sucroferric oxyhydroxide-containing granules and pharmaceutical composition |
RU2701738C1 (ru) * | 2018-10-22 | 2019-10-01 | Федеральное государственное бюджетное учреждение науки Институт химии нефти Сибирского отделения Российской академии наук (ИХН СО РАН) | Способ получения композита на основе соединений железа |
PT3930686T (pt) | 2019-02-28 | 2023-09-04 | Renibus Therapeutics Inc | Novas composições de ferro e métodos de preparação e utilização das mesmas |
US11090346B2 (en) * | 2019-05-28 | 2021-08-17 | Inbold Inc. | Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery |
WO2021137780A1 (en) * | 2019-12-30 | 2021-07-08 | İlko İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Preparation of film tablet composition comprising heme iron for iron deficiency |
CA3163438A1 (en) * | 2020-01-16 | 2021-07-22 | Vifor Fresenius Medical Care Renal Pharma, Ltd. | Particles of a mixture of iron(iii)-oxyhydroxide, sucrose and one or more starches, preferably of sucroferric oxyhydroxide |
EP3932535A1 (en) | 2020-07-01 | 2022-01-05 | Vifor Fresenius Medical Care Renal Pharma, Ltd. | Manufacturing method for polynuclear iron compounds stabilized by carbohydrates and/or humic acid |
CN113171353B (zh) * | 2021-04-25 | 2022-10-21 | 海南普利制药股份有限公司 | 一种马来酸曲美布汀片 |
CN115155537B (zh) * | 2022-07-28 | 2023-05-09 | 安徽农业大学 | FeOOH功能化腈纶纤维及其制备方法和应用 |
CN116196330A (zh) * | 2023-03-16 | 2023-06-02 | 广东赛康制药厂有限公司 | 一种治疗高磷酸血症药物的制备工艺 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2820740A (en) | 1953-02-27 | 1958-01-21 | Benger Lab Ltd | Therapeutic preparations of iron |
CH397628A (de) | 1959-05-08 | 1965-08-31 | Hausmann Ag Labor | Verfahren zur Herstellung von therapeutisch verwendbaren Eisen-(III)-hydroxyd-Polymaltose-Komplexen |
US3076798A (en) | 1961-02-23 | 1963-02-05 | Hausmann Lab Ltd | Process for preparing a ferric hydroxide polymaltose complex |
GB1200902A (en) * | 1967-05-13 | 1970-08-05 | Fisons Pharmaceuticals Ltd | Iron-dextran complexes |
AT279048B (de) | 1967-07-04 | 1970-02-25 | Pharmazeutische Fabrik Montavit Gmbh | Verfahren zur Herstellung neuer, löslicher und stabiler organischer Eisen(III)-Komplexverbindungen und Injektionslösungen davon |
US3499837A (en) | 1967-11-20 | 1970-03-10 | Johns Manville | Waste water treatment phosphate removal by iron oxide |
GB1249558A (en) | 1969-08-19 | 1971-10-13 | American Cyanamid Co | Process for the preparation of size-controlled colloidal iron sols and their stabilized solutions |
US3928581A (en) | 1972-09-13 | 1975-12-23 | Astra Laekemedel Ab | Certain polymer-iron complexes for treatment of iron deficiency |
US4181718A (en) | 1975-12-29 | 1980-01-01 | Mason Norbert S | Polyanion-stabilized aluminum hydrogels |
US4581141A (en) | 1978-02-27 | 1986-04-08 | Purdue Research Foundation | Dialysis material and method for removing uremic substances |
US4327076A (en) | 1980-11-17 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
CH650890A5 (de) | 1981-06-15 | 1985-08-15 | Edak Ag | Tragbares schutzgehaeuse fuer elektrische und elektronische geraete. |
US4474859A (en) | 1982-02-05 | 1984-10-02 | Jujo Paper Co., Ltd. | Thermal dye-transfer type recording sheet |
JPS5973576A (ja) * | 1982-09-16 | 1984-04-25 | グラクソ・グル−プ・リミテツド | ピペリジニルシクロペンタノ−ルヘプテン酸塩 |
JPS5976535A (ja) | 1982-10-22 | 1984-05-01 | Kureha Chem Ind Co Ltd | 収着剤およびその製造法 |
US4788281A (en) | 1984-01-04 | 1988-11-29 | Tosoni Anthony L | Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof |
DE3422249A1 (de) | 1984-06-15 | 1985-12-19 | Pfeifer & Langen, 5000 Köln | Wasserloesliches eisendextran und verfahren zu seiner herstellung |
US4668400A (en) | 1984-06-22 | 1987-05-26 | Veech Richard L | Hemodialysis processes and hemodialysis solutions |
US5248492A (en) | 1986-07-03 | 1993-09-28 | Advanced Magnetics, Inc. | Low molecular weight carbohydrates as additives to stabilize metal oxide compositions |
US4869828A (en) | 1988-02-26 | 1989-09-26 | Nalco Chemical Company | Stabilization of iron in aqueous systems |
US4970079A (en) * | 1989-06-05 | 1990-11-13 | Purdue Research Foundation | Method and composition of oxy-iron compounds for treatment of hyperphosphatemia |
US5213692A (en) | 1991-08-28 | 1993-05-25 | Kemiron, Inc. | Process for preparing preferred iron humates |
TW271400B (el) * | 1992-07-30 | 1996-03-01 | Pfizer | |
DE69321531T2 (de) * | 1992-08-04 | 1999-03-04 | Toda Kogyo Corp | Granulierte Teilchen für magnetische Teilchen für magnetische Aufzeichnung und Verfahren für ihre Herstellung |
DE4239442C2 (de) | 1992-11-24 | 2001-09-13 | Sebo Gmbh | Verwendung eines mit polynuklearen Metalloxidhydroxiden modifizierten Adsorptionsmaterials zur selektiven Elimination von anorganischem Phosphat aus proteinhaltigen Flüssigkeiten |
US5496545A (en) | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
US5624668A (en) | 1995-09-29 | 1997-04-29 | Luitpold Pharmaceuticals, Inc. | Iron dextran formulations |
DE19547356A1 (de) | 1995-12-19 | 1997-06-26 | Vifor Int Ag | Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung |
CN100379407C (zh) | 1997-12-19 | 2008-04-09 | 史密丝克莱恩比彻姆公司 | 生产咀嚼分散片的方法 |
GB9802201D0 (en) * | 1998-02-03 | 1998-04-01 | Cerestar Holding Bv | Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules |
UA73092C2 (uk) * | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
US6117451A (en) | 1998-08-25 | 2000-09-12 | Pharmalogix, Inc. | Direct compression metformin hydrochloride tablets |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6156332A (en) | 1999-05-27 | 2000-12-05 | Ambi, Inc. | Method and composition for masking mineral taste |
US6521247B1 (en) * | 1999-08-13 | 2003-02-18 | Warner Chilcott Laboratories Ireland Limited | Dual iron containing nutritional supplement |
AU7488001A (en) | 2000-05-22 | 2001-12-03 | Verion Inc | Method for increasing the compressibility of poorly binding powder materials |
US6358526B1 (en) | 2000-08-16 | 2002-03-19 | Rexall Sundown | Method of making tablets and tablet compositions produced therefrom |
US6576665B2 (en) | 2001-04-03 | 2003-06-10 | Braintree Laboratories, Inc. | Encapsulated calcium acetate caplet and a method for inhibiting gastrointestinal phosphorous absorption |
US6764997B2 (en) | 2001-10-18 | 2004-07-20 | Teva Pharmaceutical Industries Ltd. | Stabilized azithromycin compositions |
US20030190355A1 (en) | 2002-04-05 | 2003-10-09 | Hermelin Marc S. | Modified release minerals |
AR045068A1 (es) * | 2003-07-23 | 2005-10-12 | Univ Missouri | Formulacion de liberacion inmediata de composiciones farmaceuticas |
SI2172205T1 (sl) | 2003-08-26 | 2014-10-30 | Shire Biopharmaceuticals Holdings Ireland Limited | Farmacevtska formulacija obsegajoča lantanove spojine |
US6903235B2 (en) | 2003-10-08 | 2005-06-07 | Panion & Bf Biotech Inc. | Pharmaceutical-grade ferric citrate |
DE102004031181A1 (de) | 2004-06-28 | 2006-01-19 | Vifor (International) Ag | Phosphatadsorbens |
CN100345546C (zh) * | 2004-08-25 | 2007-10-31 | 浙江震元制药有限公司 | 氯诺昔康口腔速崩组合物及其制备方法 |
CN1302772C (zh) * | 2005-05-24 | 2007-03-07 | 中国人民解放军第二军医大学 | 阿魏酸钠口腔崩解片及其制备方法 |
EP1757299A1 (de) * | 2005-08-25 | 2007-02-28 | Vifor (International) Ag | Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung |
MY157620A (en) | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
US20080107787A1 (en) * | 2006-11-02 | 2008-05-08 | The Coca-Cola Company | Anti-Diabetic Composition with High-Potency Sweetener |
EP2319804B1 (en) * | 2006-12-14 | 2014-10-22 | Novartis AG | Iron(III)-Carbohydrate based phosphate adsorbent |
EP1932807A1 (en) * | 2006-12-14 | 2008-06-18 | Novartis AG | Inorganic compounds |
SI2319804T1 (sl) | 2006-12-14 | 2015-01-30 | Novartis Ag | Fosfatni adsorbent na osnovi Ĺľelezo(III)-ogljikovega hidrata |
TWI468167B (zh) * | 2007-11-16 | 2015-01-11 | 威佛(國際)股份有限公司 | 藥學組成物 |
AU2013203333B2 (en) | 2007-11-16 | 2015-04-02 | Vifor (International) Ag | Pharmaceutical compositions |
GB0814326D0 (en) | 2008-08-05 | 2008-09-10 | Medical Res Council | Phosphate binding materials and their uses |
DK3735962T3 (da) | 2013-11-27 | 2024-06-24 | Vifor Fresenius Medical Care Renal Pharma Ltd | Farmaceutisk sammensætning, omfattende fosfatbindemiddelspartikler |
-
2008
- 2008-11-06 TW TW097142829A patent/TWI468167B/zh active
- 2008-11-06 TW TW103118250A patent/TWI592159B/zh active
- 2008-11-13 CN CN201510131417.6A patent/CN104688702A/zh active Pending
- 2008-11-13 LT LTEP18191458.1T patent/LT3492069T/lt unknown
- 2008-11-13 EP EP16195982.0A patent/EP3143992B1/en active Active
- 2008-11-13 EP EP21176696.9A patent/EP3895699B1/en active Active
- 2008-11-13 BR BRPI0820308A patent/BRPI0820308B8/pt active IP Right Grant
- 2008-11-13 RU RU2010124424A patent/RU2493831C3/ru active Protection Beyond IP Right Term
- 2008-11-13 MX MX2010005346A patent/MX2010005346A/es active IP Right Grant
- 2008-11-13 HR HRP20230588TT patent/HRP20230588T3/hr unknown
- 2008-11-13 PL PL21176696.9T patent/PL3895699T3/pl unknown
- 2008-11-13 MY MYPI2010002266A patent/MY156383A/en unknown
- 2008-11-13 CN CN201611234717.8A patent/CN106619710A/zh active Pending
- 2008-11-13 DK DK18191458.1T patent/DK3492069T3/da active
- 2008-11-13 WO PCT/EP2008/065444 patent/WO2009062993A1/en active Application Filing
- 2008-11-13 SI SI200832210T patent/SI3895699T1/sl unknown
- 2008-11-13 EP EP21176707.4A patent/EP3895700B1/en active Active
- 2008-11-13 DK DK21176696.9T patent/DK3895699T3/da active
- 2008-11-13 KR KR1020137005435A patent/KR101590115B1/ko active Protection Beyond IP Right Term
- 2008-11-13 SI SI200831757A patent/SI2222285T1/sl unknown
- 2008-11-13 PT PT88486154T patent/PT2222285T/pt unknown
- 2008-11-13 CN CN202010986012.1A patent/CN112022821A/zh active Pending
- 2008-11-13 FI FIEP21176696.9T patent/FI3895699T3/fi active
- 2008-11-13 ES ES21176707T patent/ES2951457T3/es active Active
- 2008-11-13 SG SG2013011556A patent/SG188789A1/en unknown
- 2008-11-13 US US12/743,120 patent/US9561251B2/en active Active
- 2008-11-13 PT PT181914581T patent/PT3492069T/pt unknown
- 2008-11-13 CA CA2700444A patent/CA2700444C/en active Active
- 2008-11-13 ES ES18191458T patent/ES2908719T3/es active Active
- 2008-11-13 ES ES08848615.4T patent/ES2612331T3/es active Active
- 2008-11-13 HU HUE08848615A patent/HUE031293T2/en unknown
- 2008-11-13 AU AU2008322963A patent/AU2008322963B2/en active Active
- 2008-11-13 NZ NZ585435A patent/NZ585435A/en unknown
- 2008-11-13 AR ARP080104959A patent/AR069312A1/es not_active Application Discontinuation
- 2008-11-13 CN CN202010986126.6A patent/CN112022822A/zh active Pending
- 2008-11-13 EP EP08848615.4A patent/EP2222285B1/en not_active Revoked
- 2008-11-13 PT PT211766969T patent/PT3895699T/pt unknown
- 2008-11-13 HR HRP20220318TT patent/HRP20220318T1/hr unknown
- 2008-11-13 ES ES16195982T patent/ES2703158T3/es active Active
- 2008-11-13 DK DK08848615.4T patent/DK2222285T3/en active
- 2008-11-13 PL PL18191458T patent/PL3492069T3/pl unknown
- 2008-11-13 EP EP21176683.7A patent/EP3895698A3/en active Pending
- 2008-11-13 DK DK16195982.0T patent/DK3143992T3/en active
- 2008-11-13 CN CN200880116176A patent/CN101861146A/zh active Pending
- 2008-11-13 KR KR1020107013304A patent/KR101438071B1/ko active Protection Beyond IP Right Term
- 2008-11-13 SI SI200832190T patent/SI3492069T1/sl unknown
- 2008-11-13 SI SI200832030T patent/SI3143992T1/sl unknown
- 2008-11-13 PL PL16195982T patent/PL3143992T3/pl unknown
- 2008-11-13 LT LTEP08848615.4T patent/LT2222285T/lt unknown
- 2008-11-13 CN CN202010986348.8A patent/CN112022796A/zh active Pending
- 2008-11-13 PH PH12015500727A patent/PH12015500727A1/en unknown
- 2008-11-13 JP JP2010533575A patent/JP5466164B2/ja active Active
- 2008-11-13 PL PL08848615T patent/PL2222285T3/pl unknown
- 2008-11-13 LT LTEP16195982.0T patent/LT3143992T/lt unknown
- 2008-11-13 MY MYPI2015001080A patent/MY193729A/en unknown
- 2008-11-13 EP EP18191458.1A patent/EP3492069B1/en active Active
- 2008-11-13 PT PT16195982T patent/PT3143992T/pt unknown
- 2008-11-13 HU HUE16195982A patent/HUE041429T2/hu unknown
- 2008-11-13 PT PT211767074T patent/PT3895700T/pt unknown
- 2008-11-13 CN CN202010896640.0A patent/CN111789820A/zh active Pending
- 2008-11-13 ES ES21176696T patent/ES2950337T3/es active Active
- 2008-11-15 SA SA112340044A patent/SA112340044B1/ar unknown
-
2010
- 2010-04-08 TN TN2010000152A patent/TN2010000152A1/fr unknown
- 2010-05-13 IL IL205726A patent/IL205726A/en active IP Right Grant
- 2010-05-14 CO CO10058238A patent/CO6280398A2/es not_active Application Discontinuation
- 2010-05-14 GT GT201000144A patent/GT201000144A/es unknown
- 2010-06-03 MA MA32888A patent/MA31898B1/fr unknown
- 2010-06-15 ZA ZA2010/04256A patent/ZA201004256B/en unknown
-
2013
- 2013-06-20 RU RU2013128356A patent/RU2648760C3/ru active Protection Beyond IP Right Term
- 2013-12-12 JP JP2013257490A patent/JP5961601B2/ja active Active
-
2015
- 2015-04-23 JP JP2015088748A patent/JP6294260B2/ja active Active
- 2015-08-18 HK HK15107932.9A patent/HK1207298A1/xx unknown
-
2016
- 2016-09-11 IL IL247741A patent/IL247741B/en active IP Right Grant
- 2016-12-23 US US15/389,549 patent/US10780113B2/en active Active
-
2017
- 2017-01-10 HR HRP20170034TT patent/HRP20170034T1/hr unknown
- 2017-01-24 CY CY20171100099T patent/CY1118496T1/el unknown
- 2017-02-01 JP JP2017016971A patent/JP6538734B2/ja active Active
-
2018
- 2018-10-25 US US16/170,650 patent/US10682376B2/en active Active
- 2018-11-06 HR HRP20181837TT patent/HRP20181837T1/hr unknown
- 2018-11-27 US US16/200,943 patent/US10695367B2/en active Active
- 2018-12-19 CY CY20181101376T patent/CY1121230T1/el unknown
-
2019
- 2019-02-01 JP JP2019016592A patent/JP6764959B2/ja active Active
-
2020
- 2020-06-19 US US16/906,584 patent/US10925896B2/en active Active
- 2020-06-19 US US16/906,648 patent/US10925897B2/en active Active
- 2020-07-17 US US16/932,124 patent/US10933090B2/en active Active
- 2020-09-14 JP JP2020153832A patent/JP7216055B2/ja active Active
-
2021
- 2021-01-15 US US17/150,529 patent/US11013761B1/en active Active
- 2021-01-15 US US17/151,064 patent/US11013762B1/en active Active
- 2021-04-22 US US17/302,065 patent/US20220072035A1/en not_active Abandoned
- 2021-12-16 US US17/644,632 patent/US20220105129A1/en active Pending
- 2021-12-16 US US17/644,643 patent/US20220105131A1/en active Pending
- 2021-12-16 US US17/644,637 patent/US20220105130A1/en active Pending
-
2022
- 2022-03-21 CY CY20221100224T patent/CY1125300T1/el unknown
- 2022-11-07 JP JP2022177769A patent/JP2023011873A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121230T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου | |
CY1122187T1 (el) | Αντιγονικη συνθεση μυκοβακτηριου | |
CY1122786T1 (el) | Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης | |
CY1121125T1 (el) | Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης | |
CY1119177T1 (el) | Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτα και μεθοδοι χρησης αυτων | |
CY1118396T1 (el) | Θερμοπητικες αναισθητικες συνθεσεις | |
CY1119436T1 (el) | Σκευασμα για αντισωμα εναντι- 4 7 | |
CY1116150T1 (el) | Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842 | |
LTC1608344I2 (lt) | Per burną vartojamos kladribino kompozicijos | |
CY1117237T1 (el) | Συνθεσεις σταθερων τιακουμυκινων | |
CY1113869T1 (el) | Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf | |
CY1118250T1 (el) | Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων | |
ECSP099577A (es) | Formulaciones para el tratamiento del cáncer | |
CY1116264T1 (el) | Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2 | |
CY1110221T1 (el) | Σταθερα φαρμακευτικα σκευασματα νατριουχου μοντελουκαστης | |
CY1114793T1 (el) | Παραγωγα αμινοπυραζολιου | |
CL2008003406A1 (es) | Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih. | |
CY1108660T1 (el) | Υγρες φαρμακευτικες τυποποιησεις παλονοσετρονης | |
CY1123382T1 (el) | Απο του στοματος και ενεσιμα και σκευασματα ενωσεων τετρακυκλινης | |
CL2008001123A1 (es) | Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
GT200800107A (es) | Formulaciones orales que comprenden tigeciclina | |
CY1111456T1 (el) | Συνθεσεις περιλαμβανουσες νεραμεξανη | |
CY1117541T1 (el) | Αντικαρκινικες στεροειδεις λακτονες μη κορεσμενες στη θεση 7(8) | |
CY1118967T1 (el) | Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης | |
MX2009012370A (es) | Formulacion de antraciclina de baja viscosidad. |